Ainos (NASDAQ:AIMD) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Analysis

Xenetic Biosciences (NASDAQ:XBIO) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Profitability

This table compares Xenetic Biosciences and Ainos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-110.42%	-64.66%	-54.63%
Ainos	N/A	-119.36%	-58.78%

Earnings and Valuation

This table compares Xenetic Biosciences and Ainos”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.50 million	2.13	-$3.96 million	($2.05)	-1.14
Ainos	$20,000.00	370.37	-$14.86 million	($3.98)	-0.39

Xenetic Biosciences has higher revenue and earnings than Ainos. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Xenetic Biosciences has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, Ainos has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Xenetic Biosciences and Ainos, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1	1	0	0	1.50
Ainos	1	0	0	0	1.00

Insider and Institutional Ownership

15.1% of Xenetic Biosciences shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Comparatively, 9.8% of Ainos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Xenetic Biosciences beats Ainos on 7 of the 12 factors compared between the two stocks.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.